Volition's Nu.Q® NETs Biomarker Validated for Sepsis Mortality Prediction
Event summary
- Volition's Nu.Q® NETs H3.1 biomarker validated as an independent predictor of 28-day mortality and need for renal replacement therapy (RRT) in sepsis patients.
- Study published in Critical Care Medicine demonstrates higher biomarker levels in septic shock patients with a clear dose-response relationship to acute kidney injury severity.
- Total addressable market for Nu.Q® NETs in sepsis estimated at $2.8 billion.
- Volition advancing commercial discussions with diagnostic industry players.
The big picture
This validation positions Volition's biomarker technology as a potential game-changer in sepsis management, where early intervention is critical. The $2.8 billion addressable market represents significant commercial potential, particularly as diagnostic companies seek to differentiate their sepsis offerings. The findings could also accelerate research into NETosis-related therapeutic approaches.
What we're watching
- Commercialization Pace
- How quickly Volition can convert clinical validation into licensing agreements and revenue streams.
- Market Adoption
- Whether hospitals will integrate Nu.Q® NETs into sepsis management protocols despite existing diagnostic options.
- Therapeutic Applications
- The pace at which biomarker insights translate into targeted sepsis treatments.
Related topics